EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial

Shizuya Yamashita iD, Tsutomu Hirano, Hitoshi Shimano, Kazuhisa Tsukamoto, Masayuki Yoshida, Hiroshi Yoshida iD

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14227 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Shizuya Yamashita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rinku General Medical Center, Izumisano, Osaka, Japan. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Cardiovascular Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Numerous epidemiological studies have shown that hypertriglyceridemia is a significant risk factor for cardiovascular diseases (CVD). However, large clinical studies on triglyceride‐lowering therapy have yielded inconsistent results. In the current review, we reassess the importance of triglyceride‐lowering therapy in preventing CVD based on previous literature and the recently published findings of the PROMINENT trial.

Methods

This narrative review is based on literature and public documents published up to November 2023.

Results

Meta‐analyses of trials on peroxisome proliferator‐activated receptor α agonists and triglyceride‐lowering therapy, including the PROMINENT trial, have indicated that triglyceride‐lowering therapy can reduce CVD events. Mendelian randomization studies have also indicated that triglyceride is indeed a true risk factor for coronary artery disease, leaving no doubt about its relationship to CVD. Meanwhile, the negative results from the PROMINENT trial were likely due to the insufficient triglyceride‐lowering effect, slight increases in low‐density lipoprotein cholesterol and apolipoprotein B, and the inclusion of mostly high‐intensity statin users as target patients. It is unlikely that adverse events counteracted the effectiveness of pemafibrate on outcomes. Additionally, pemafibrate has shown positive effects on non‐alcoholic fatty liver disease and peripheral artery disease.

Conclusion

Although the PROMINENT trial did not demonstrate the significance of pemafibrate as a triglyceride‐lowering therapy in a specific population, it does not necessarily negate the potential benefits of treating hypertriglyceridemia in reducing CVD events. It is necessary to explore appropriate populations that could benefit from this therapy, utilize data from the PROMINENT trial and other databases, and validate findings in real‐world settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertriglyceridemiaCardiovascular DiseasesHumansHypolipidemic AgentsTriglyceridesHydroxymethylglutaryl-CoA Reductase InhibitorsBenzoxazolesNon-alcoholic Fatty Liver DiseaseCoronary Artery DiseaseCholesterol, LDLRandomized Controlled Trials as TopicButyrates

Stichwörter der Autor:innen

CVD eventPPARα agonistsPROMINENTpemafibratetriglyceridetype 2 diabetes

Substanzen

Hypolipidemic AgentsTriglyceridesHydroxymethylglutaryl-CoA Reductase InhibitorsBenzoxazoles(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidCholesterol, LDLButyrates

Autor:innen und Institutionen

  • Rinku General Medical Center, Izumisano, Osaka, Japan.
  • Diabetes Center, Ebina General Hospital, Ebina, Kanagawa, Japan.
  • Department of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Medical Genetics, Tokyo Medical and Dental University, Tokyo, Japan.
  • Department of Life Science and Bioethics, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

ORCID-Profile: Shizuya Yamashita, Hiroshi Yoshida

Zitieren

APA

Yamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024). Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14227

Vancouver

Yamashita S, Hirano T, Shimano H, Tsukamoto K, Yoshida M, Yoshida H. Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14227

BibTeX
@article{Yamashita2024,
  author = {Yamashita, Shizuya and Hirano, Tsutomu and Shimano, Hitoshi and Tsukamoto, Kazuhisa and Yoshida, Masayuki and Yoshida, Hiroshi},
  title = {Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14227}
}
Kostenlos starten →